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Background: Lipin-2 is a lipid metabolic 
enzyme.  
Results: Lipin-2 levels control the generation of 
proinflammatory factors in macrophages 
overloaded with saturated fatty acids. 
Conclusions: Lipin-2 has an anti-inflammatory 
action under fatty acid overload conditions. 
Significance: Lipin-2 is involved in the cross-
talk between lipid metabolism and 
inflammation.  
 
SUMMARY 
Lipin-2 is a member of the lipin family of 
enzymes, which are key effectors in the 
biosynthesis of lipids. Mutations in the 
human lipin-2 gene are associated with 
inflammatory-based disorders, however the 
role of lipin-2 in cells of the immune system 
remains obscure. In the present work we have 
investigated the role of lipin-2 in the 
proinflammatory action of saturated fatty 
acids in murine and human macrophages. 
Depletion of lipin-2 promotes the increased 
expression of the proinflammatory genes Il6, 
Ccl2 and Tnfα, which depends on the 
overstimulation of the JNK1/c-Jun pathway 
by saturated fatty acids. On the contrary, 
overexpression of lipin-2 reduces the release 
of proinflamatory factors. Metabolically, the 
absence of lipin-2 reduces the cellular content 
of triacylglycerol in saturated fatty acid-
overloaded macrophages. Collectively, these 
studies demonstrate a protective role for 
lipin-2 in proinflammatory signaling 
mediated by saturated fatty acids that occurs 
concomitant with an enhanced cellular 
capacity for triacylglycerol synthesis. The 
data provide new insights into the role of 
lipin-2 in human and murine macrophage 
biology, and may open new avenues for 
controlling the fatty acid-related low grade 
inflammation that constitutes the sine qua 
non of obesity and associated metabolic 
disorders. 
 
Chronic low grade inflammation 
produced in the adipose tissue during obesity is, 
at least in part, due to the increased levels of 
fatty acids released from adipocytes, especially 
saturated fatty acids, that are able to stimulate 
tissue resident macrophages and change their 
polarization state from an anti-inflammatory 
(M2) to a proinflammatory state (M1) (1). 
Persistent activation of inflammatory pathways 
and the interplay macrophage/adipocyte are 
important events in the pathogenesis of insulin 
resistance, which can herald the onset of type 2 
diabetes (2). For these reasons, there is much 
interest in the study of macrophage activation by 
saturated fatty acids and the molecular 
mechanisms that control their proinflammatory 
action.  
 Saturated fatty acids can affect cellular 
homeostasis by different pathways that could 
eventually cross-talk. They can activate TLR4 
and TLR2, two members of the Toll-like 
receptor family that recognizes microorganisms 
and triggers host responses (3). The interaction 
of TLR4/2 receptors with their canonical ligands 
(Gram-negative bacterial 
lipopolysaccharide/lipopeptides) induces an 
intracellular signaling cascade that activates 
kinases of the mitogen-activated protein kinase 
(MAPK)5 family and adaptor molecules, and 
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ends in the activation of key proinflammatory 
transcription factors such as AP-1 and NF-κB 
(4-6). Among the MAPK family of enzymes, 
JNK1 is a relevant player in the control of the 
activation of hypertrophic adipose tissue 
infiltrating macrophages by fatty acids (3,7). 
JNK1 expression in hematopoietic cells governs 
diet induced inflammation and insulin resistance 
without affecting obesity (8). On the other hand, 
high saturated fatty acid concentrations show 
ability to induce endoplasmic reticulum (ER) 
stress, triggering the unfolded protein response 
(UPR), a complex cellular reaction mounted to 
restore cellular homeostasis that may ultimately 
affect the induction of proinflammatory genes 
via JNK activation (8-10).  
 Saturated fatty acids, like other fatty 
acids, are also internalized into the cells and 
incorporated into triacylglycerol (TAG). 
Recently it has been shown that the capacity of 
macrophages to store saturated fatty acids into 
TAG correlates inversely with their capacity to 
express proinflammatory genes and undergo M1 
polarization, perhaps by reducing the 
intracellular concentration of free saturated fatty 
acids and hence their modulation of 
proinflammatory pathways (11).  
 Along the biosynthetic pathway of 
TAG, lipins, also known as Mg2+-dependent 
phosphatidic acid phosphatases, are in charge of 
the generation of diacylglycerol (DAG) pools to 
be acylated by the action of diacylglycerol:acyl-
CoA acyltransferases (DGATs) (12). 
Interestingly, before their enzymatic activity was 
revealed, lipins had been described as proteins 
implicated in the development of fat deposits 
(13-15). The DAG pools generated by lipins can 
also be used for the synthesis of the major 
membrane phospholipids phosphatidylcholine 
and phosphatidylethanolamine (16). Perhaps 
because of their key cellular roles, very few 
known illnesses associated with genetic 
alterations of lipins have been described (17). 
Among the three different genes that encode 
lipin proteins (lipin-1, 2 and 3), mutations in 
LPIN2 results in Majeed syndrome, a recessive 
Mendelian rare disease characterized by 
recurrent episodes of fever and inflammation in 
bone and skin, and congenital dyserythropoietic 
anemia (18). Psoriasis, a skin inflammatory 
disease, is also associated with LPIN2 mutations 
(19). Thus, human diseases that have been 
linked to mutations of LPIN2 seem to have an 
inflammatory foundation. These observations 
led us to speculate with a role for lipin-2 in the 
regulation of inflammatory processes. In the 
present study we have identified lipin-2 as an 
unexpected player in the proinflammatory action 
of saturated fatty acids in both monocyte-
derived human macrophages and the murine 
macrophage cell line RAW 264.7. Our studies 
indicate that lipin-2 is an anti-inflammatory 
enzyme that controls TAG synthesis, JNK/AP-1 
pathway activation and ultimately, the 
upregulation of proinflammatory genes.  
 
EXPERIMENTAL PROCEDURES 
Reagents - Fatty acids, antibody against β-actin, 
SP600125, and PD98059 were obtained from 
Sigma-Aldrich. Antibodies against ERK, 
phospho-ERK (Thr 202-Tyr 204), JNK, 
phospho-JNK (Thr 183-Tyr 185), phospho-c-
Jun, c-Jun, were purchased from Cell Signalling 
(Danvers, MA). BODIPY493/503, was 
purchased from Molecular Probes-Invitrogen 
(Carlsbad, CA). Human macrophage 
Nucleofection solution was from Amaxa 
(Gaithersburg, MD). ON-Target plus siRNAs 
against mice mRNAs were obtained from 
Dharmacon, and siRNAs Silencer Select against 
human mRNAs was obtained from Ambion. 
Cells – Human blood monocyte-derived 
macrophages were obtained from buffy coats of 
healthy volunteer donors obtained from the 
Centro de Hemoterapia y Hemodonación de 
Castilla y León (Valladolid, Spain) as previously 
described (20-22). Murine RAW 264.7 
macrophages were maintained in  DMEM 
medium supplemented with 10% FBS, 100 U/ml 
penicillin, 100 μg/ml streptomycin, and 2 mM 
glutamine at 37°C in a 5% CO2 humidified 
incubator. Palmitic acid and oleic acid were 
complexed to BSA (2:1 molar ratio) as described 
(23). For gene expression analysis, an 8-h time 
treatment of cells with fatty acids was used, 
based on time-course experiments. 
PCR - RNA was extracted using TRIzol reagent 
method (Invitrogen Life Technologies) 
according to the manufacturer´s protocol. First-
strand cDNA was then obtained by using the 
Moloney murine leukemia virus reverse 
transcriptase from 1 μg RNA. PCR was then 
performed using specific primers for Lipin1α, 
1β, 2 and 3 mRNA (see below). 
Real-time PCR - RNA was extracted using 
TRIzol reagent method (Invitrogen Life 
Technologies). First-strand cDNA was 
synthesized from 2 μg of total RNA using the 
Transcriptor First Strand cDNA Synthesis kit 
 2
Protective Role of Lipin-2 in Inflammation 
(Roche Applied Science, Barcelona, Spain) and 
random primers. The cDNA was amplified by 
real-time PCR using the KAPA SYBR Master 
mix qPCR (Roche) and specific primers for each 
gene (24). Sequences of the primers used for 
murine genes were as follows: Cyclophilin, 5´-
TGGAAGAGCCAAGACAGACA-3´ and 5'-
GCCGGAGTCGACAATGAT-3'; Lpin1, 5´-
CTCCGCTCCCGAGAGAAG-3´and 5´-
TCATGTGCAAATCCACGGACT-3´; 
Lpin1α, 5´-GGTCCCCAGCCCCAGTCCTT-3´ 
and 5´-GCAGCCTGTGGCAATTCA-3´; 
Lpin1β, 5´-CATGCTTCGGAAAGTCCTTCA-
3´ and 5´-GGTTATTCTTTGGCGTCAACCT-
5´; Lpin2, 5´-AGTTGACCCCATCACCGTAG-
3´ and 5´-CCCAAAGCATCAGACTTGGT-3´; 
Lpin3, 5´-TGGAATTGGGATGACAAGGT-3´ 
and 5´-CCCAAAGCATCAGACTTGGT-3´; 
Tnfα, 5´-ACGGCATGGATCTCAAAAGAC-3´ 
and 5´-AGATAGCAAATCGGCTGACG-3´; 
Ccl2, 5´-AGGTCCCATGTCATGCTTCTGG-3´ 
and 5´-CTGCTGCTGGTGATCCTCTTG-3´; 
Il6, 5´-TAGTCCTTCCTACCCCAATTTCC-3´ 
and 5´-TTGGTCCTTAGCCACTCCTTC-5´. 
Primers for human genes were: Cyclophilin, 
5´CAGACAAGGTCCCAAAGACAG-3´ and 
5´-TTGCCATCCAACCACTCAGTC-3´; 
LPIN1α, 5´-
TGCTGGAGAGCAGCAGAACTC-3´ and 5´-
GAACCGGAAGGACTGGGAGTG-3´; 
LPIN1β, 5´-
TGCTGGAGAGCAGCAGAACTC-3´ and  5´-
AAGACTGTGGAGGGCAAGAAC-3´; LPIN2, 
5´-CCTCTCCTCAGACCAGATCG-3´ and 5´-
GGAGAATCTGTCCCAAAGCA-3´; LPIN3, 
5´-CACTCCACCCTCCACTCCTA-3´ and 5´-
ACAGGTAGATGGTGGCCTTG-3´; TNFα, 5´-
ATGAGCACTGAAAGCATGATCC-3´ and 5´-
GAGGGCTGATTAGAGAGAGGTC-3´; 
CCL2, 5´-CAGCCAGATGCAATCAATGCC-
3´ and 5´-TGGAATCCTGAACCCACTTCT-3´; 
IL6, 5´-AAATTCGGTACATCCTCGACGG-3´ 
and 5´-GGAAGGTTCAGGTTGTTTTCTGC-
3´. Primers for LPIN1α and 1β were from the 
reference: 25. The relative mRNA abundance for 
a given gene was calculated using the ΔΔCT 
method, using cyclophilin as the internal 
standard (26). 
Constructs and transfections - Lipin2-EGFP 
plasmid was generated by introducing the cDNA 
sequence of the mouse lpin2 (Thermo Scientific, 
clon #5101211) in the EGFP expression vector 
pEGFP-N3 (Clontech) by using HindIII and SalI 
restriction enzymes. The primers used were: 5´-
CACACAAAGCTTAAATGAATTATGTGGG
CCAGCT-3´ and 5´-
CACACAGTCGACAGCCAGGTCATCCAGG
TCC-3´. Confirmation of the correct insertion of 
the cDNA was performed by sequencing. 
Plasmids (EGFP or lipin2-EGFP) were 
transfected using LipofectamineTM LTX and 
PLUSTM reagents following the manufacturer’s 
instructions. After 24 h transfection, fluorescent 
cells were selected by cell sorting using a FACS 
Aria. Cells were allowed to recover for 48 h in 
the presence of 1 mg/ml geneticin and then used 
for experiments. At that time, more of 90% of 
the cells exhibited fluorescence. 
Small interfering RNA (siRNA) transfection - 
RAW 264.7 cells (2 x 105) were transiently 
transfected with siRNAs (20 nM) in the presence 
of 5 μl/ml LipofectamineTM RNAiMAX 
(Invitrogen Life Technologies) under serum-free 
conditions for 5 h. Afterward, 5% serum was 
added and the cells were maintained at normal 
culture conditions for 48 h.  A scrambled siRNA 
was used as a negative control. By using a 
negative fluorescent siRNA, we estimated that 
95% of the cells were transfected. Also, the 
siRNAs produced a 70–90% reduction in the 
expression of the corresponding targets. 
Transfection of human macrophages was 
achieved by the Nucleofection method as 
previously described (20).  
Immunoblot - After cellular stimulation, cells 
were lysed with 20 mM Tris-HCl  (pH 
7.4),containing 150 mM NaCl, 0.5% Triton X-
100, 1 mM Na3VO4, 150 mM NaF, 1 mM 
PMSF, and a protease inhibitor mixture (Sigma-
Aldrich) at 4°C. Homogenates were then 
clarified by centrifugation at 13,000 x g for 10 
min. Protein from the supernatants was 
quantified by the Bradford protein assay kit 
(Bio-Rad), and 100 μg of protein was analyzed 
by immunoblot using specific antibodies. 
Detection of immunoreactive bands was 
conducted by chemoluminiscence (ECLTM, 
Amersham) using a Bio-Rad VersaDoc 5000 
system. The resulting digital images were 
analyzed for quantitative band densitometry at 
different time exposures within the linear 
response defined by Quantity One software 
(version 4.5.2; Bio-Rad).  
IL-6, TNF-α and MCP-1 quantification - After 
cellular activation, supernatants were used for 
quantification of IL-6, TNF-α and MCP-1 by 
specific ELISA kits (eBioscience, San Diego, 
CA) following the manufacturer’s instructions. 
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Flow cytometry - After the various treatments, 
cells were scraped, washed with phosphate-
buffered saline and stained with 0.2 μg/ml 
BODIPY 493/503 for 5 min as previously 
described (20). Cells were washed and 
fluorescence was analyzed by flow cytometry in 
a FACS Gallios (Beckman Coulter) using the 
FL1 detector. Fluorescence data was measured 
in linear scale. 
DNA-binding assays - The DNA-binding 
activity of nuclear c-Jun was assayed by a 
commercial kit (Active Motif) following the 
manufacturer’s instructions. Nuclear extract 
from activated cells were prepared as previously 
described (27). 
Microscopy - After treatments, cells were 
stained with 2 μg/ml BODYPY 493/503 for 5 
min. Then, cells were washed with PBS, fixed 
with 4% paraformaldehide and mounted using 
an antifade medium. Fluorescence was 
monitored by confocal microscopy using a Bio-
Rad Radiance 2100 laser-scanning system 
coupled to a Nikon TE-2000U. The objective 
was CFI Plan Apo 60X, 1.4 numerical aperture, 
oil immersion. The fluorescence of BODIPY 
493/503 was monitored at 488 nm Argon 
excitation using the combination of a long pass 
filter HQ500LP and a short pass filter 
HQ560SP.   
TAG analysis by mass spectrometry - Analysis 
of the fatty acids of TAG was performed by gas 
chromatography/mass spectrometry. Briefly, the 
total cellular TAG fraction isolated by thin layer 
chromatography with hexane/ether/acetic acid 
(70:30:1, v/v/v) as a mobile phase, was 
transmethylated with 500 µl of 0.5 M KOH in 
MeOH for 30 min at 37 °C. One volume of 0.5 
M HCl was added to neutralize, and fatty acid 
methyl esters were extracted twice with 2 
volumes of n-hexane. Analysis of fatty acid 
methyl esters was carried out in an Agilent 
7890A gas chromatograph coupled to an Agilent 
5975C mass selective detector (MSD) operated 
in electron impact mode (70 eV), equipped with 
an Agilent DB23 column (60 m x 0.25 mm inner 
diameter  x 0.15 µm film thickness), under the 
conditions described previously (28,29). Data 
acquisition was carried out both in scan, for 
identification, and selected ion monitoring 
(SIM) mode for quantitation, using 74 and 87 
fragments for saturated, 83 for monounsaturated, 
67 and 81 for diunsaturated and 79 and 91 for 
polyunsaturated fatty acid methyl esters. A 37-
component mixture from Supelco was used for 
calibration curves, and nonadecanoic acid was 
used as an internal standard. Data analysis was 
carried out with the Agilent G1701EA MSD 
Productivity Chemstation software, revision 
E.02.00. 
Statistical Analysis - Experiments were carried 
out at least three times in duplicate or triplicate. 
Statistical analysis was carried out by the 
Student’s t test, with p values <0.05 taken as 
statistically significant. 
 
RESULTS 
Lipin-2 levels regulate the expression of 
proinflammatory genes – Saturated fatty acids 
activate macrophages and induce the production 
of proinflammatory cytokines (30). Because 
lipins can participate in macrophage signaling 
cascades by impacting on cellular concentrations 
of DAG and phosphatidic acid (31-33), we 
began our study by testing whether lipins could 
be involved in the upregulation of 
proinflammatory genes under 
pathophysiologically relevant conditions, i.e. 
exposure of the cells to high concentrations of 
palmitic acid. For this purpose, lipin levels were 
decreased by siRNA technology.  RAW 264.7 
macrophages express the three types of lipins 
known to date, lipin 1, 2 and 3 (Fig. 1A), and 
conditions were established to achieve silencing 
of all three forms (Fig 1B). Inhibition of lipin-2 
expression but not of lipin-1 or lipin-3 resulted 
in a strong enhancement of the induction of the 
proinflammatory genes Il6, Ccl2, and Tnfα by 
palmitic acid (Fig. 1C).  In the absence of 
palmitic acid stimulation, reduction of the 
expression of any of the lipins did not alter the 
basal expression level of the genes under 
analysis. Importantly, the enhancing effect of 
lipin-2 depletion on the expression of 
proinflammatory genes was found to be 
selective for palmitic acid stimulation, since 
treating the cells with oleic acid, a 
monounsaturated fatty acid, showed a much 
lower effect (Fig. 2A). ELISA measurements 
confirmed that the increased expression of Il6, 
Ccl2, and Tnfα, in lipin-2-depleted, palmitic 
acid-stimulated cells did result in increased 
synthesis of their protein products, IL-6, MCP-1, 
and TNFα, respectively (Fig. 2B). To 
characterize further the effect of lipin-2 on 
proinflammatory gene expression, cellular levels 
of this protein were increased by transfecting the 
cells with a lipin-2-EGFP plasmid. The 
induction of proinflammatory cytokines by 
palmitic acid was reduced in cells 
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overexpressing lipin-2 with respect to control 
cells transfected only with the EGFP plasmid 
(Fig. 2C). Collectively, these data suggest that 
lipin-2 plays a key regulatory role in 
proinflammatory gene expression by 
macrophages exposed to saturated fatty acids. 
Lipin-2 regulates proinflammatory 
cytokine production via JNK1 – Members of the 
MAPK family, especially JNK, have been 
implicated in the proinflammatory stimulation of 
macrophages by fatty acids (3,8,30). Therefore, 
the impact of lipin-2 on the 
phosphorylation/activation status of different 
MAPKs after palmitic acid treatment was 
studied. Treatment of the macrophages with 
palmitic acid significantly induced the 
phosphorylation of ERKs (p42/p44) and JNK1 
(Fig. 3). When the cells were transfected with 
siRNA against lipin-2 palmitic acid treatment 
promoted a clear enhancement of the 
phosphorylation of the above-mentioned kinases 
(Fig. 3). These results demonstrate that lipin-2 
limits the activation of ERK and JNK induced 
by palmitic acid in macrophages. 
The involvement of JNK and ERK in 
the increased production of proinflammatory 
genes by lipin-2-depleted, palmitic acid-treated 
cells was studied next. The inhibitors SB600125 
—specific for JNK (34)— and PD98059 —
specific for MEK1/2, i.e. the kinase that 
phosphorylates and activates the ERKs (35)— 
were initially used for this purpose. As shown in 
Fig. 4A, the expression of Tnfα, Ccl2 and Il6, 
was strongly inhibited by SB600125 in palmitic 
acid-treated cells. Importantly, SB600125 was 
also capable of inhibiting the up-regulation of 
these genes in lipin-2-depleted cells (Fig. 4A). 
Confirmation of this effect at the protein level 
was obtained by measuring protein levels of IL-
6, MCP-1 and TNF-α by specific ELISAs (Fig. 
4B). In contrast to the data obtained with 
SB600125, the effect of PD98059 was not as 
pronounced, suggesting a lesser role for ERKs in 
mediating these processes.  
To further substantiate the above 
findings, siRNAs against JNK1 were utilized 
next. Cells depleted of JNK1 demonstrated a 
strong inhibition of mRNA and protein levels of 
the aforementioned proinflammatory factors in 
response to palmitic acid, both in control siRNA 
transfected cells and in lipin-2-depleted cells 
(Figs. 5A and 5B). From these data, it is 
apparent that JNK1 constitutes an obligatory key 
component of the signaling cascade triggered by 
palmitic acid which leads to the induction of 
proinflammatory genes, and that this cascade 
can be overstimulated when lipin-2 is decreased. 
Lipin-2 regulates the activation of c-Jun 
– Among many other proteins, JNK 
phosphorylates c-Jun, a member of the Jun 
family of proteins that forms part of the 
transcription factor AP-1, implicated in the 
transcriptional regulation of different 
proinflammatory genes (36). Thus, the possible 
role of c-Jun during palmitic acid activation and 
its regulation by lipin-2 was analyzed. 
Interestingly, it was appreciated that 
phosphorylation of c-Jun increased in cells 
lacking lipin-2 at almost all the time points 
tested (Fig. 6A). Nuclear c-Jun activation was 
assayed using a commercially available kit 
(Active motif), and a clearly enhanced activation 
of c-Jun by palmitic acid was observed when 
lipin-2-depleted cells were used (Fig. 6B). Such 
enhancement was inhibited by SP600125, 
providing further evidence that JNK is critically 
involved under these conditions (Fig, 6B). By 
using siRNA technology, the effect of c-Jun on 
the capacity of the cells to produce 
proinflammatory mediators in response to 
palmitic acid was analyzed next. Depletion of 
cellular c-Jun levels inhibited the upregulation 
of mRNA for Il6, Ccl2, and Tnfα, an effect that 
was particularly striking when lipin-2-depleted 
cells were used (Fig. 6C). Thus, these data 
demonstrate that the extent of JNK-mediated c-
Jun activation in palmitic acid-treated cells is 
controlled by lipin-2. 
Lipin-2 regulates the incorporation of 
fatty acids in TAG in macrophages — The 
enzymatic activity of lipins (Mg2+-dependent 
phosphatidic acid phosphatases) is centrally 
involved in the de novo synthesis of lipids (37). 
Because the specific role of the various lipin 
isoforms in lipid metabolism in macrophages 
and other cells is not well defined, studies were 
conducted to assess whether lipin-2 plays a 
regulatory role in TAG synthesis by 
macrophages exposed to saturated fatty acids. 
Since TAG molecules are stored in cytoplasmic 
lipid droplets, these organelles were studied by 
microscopy after staining with BODIPY 
493/503. As shown in Fig. 7A, depletion of 
lipin-2 by siRNA resulted in a considerable 
reduction of the lipid droplet content of 
macrophages. These results were confirmed by 
flow cytometry, which allows quantification 
(Fig. 7B). Direct measurements of total TAG 
mass were carried out by mass spectrometry. 
Cell treatment with palmitic acid increased 
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cellular TAG content by about 30% (Fig. 7C). 
However, in the absence of lipin-2, palmitic acid 
induced-TAG synthesis was strongly reduced, 
thus demonstrating the key role of lipin-2 in this 
process. Analyses of the fatty acid composition 
of TAG in the RAW264.7 macrophages revealed 
that this neutral lipid was composed almost 
exclusively of palmitic acid (16:0) and stearic 
acid (18:0). The content of both fatty acids 
increased in TAG after exposure of the cells to 
palmitic acid, but that did not happen when 
lipin-2-depleted cells were used (Fig. 7D). 
Human macrophages exhibit an 
exacerbated proinflammatory response in the 
absence of lipin-2. Experiments were also 
conducted with human blood monocyte-derived 
macrophages to assess whether our observations 
with RAW264.7 macrophages could be 
extended to primary cells and thus bear 
pathophysiological relevance. Like RAW 264.7 
macrophages, human macrophages also express 
LPIN1α, 1β, 2 and 3 mRNAs (Fig. 8A). 
Treatment of human macrophages with palmitic 
acid induced the expression of the 
proinflammatory genes Il6 and Tnfα, and the 
lack of lipin-2 promoted a very marked up-
regulation of them (Fig. 8B). In these cells a 
quantitative depletion of lipin-2 (>80%) was 
achieved by siRNA technology (Fig. 8C). Also, 
in agreement with the results mentioned above, 
TAG mass measurements by mass spectrometry 
confirmed that depletion of lipin-2 strongly 
reduced the TAG content in human 
macrophages after palmitic acid treatment (Fig. 
8D). Note that the basal TAG content in human 
macrophages is very high. In these cells, 9 fatty 
acids were readily detectable in TAG (Fig. 8E). 
Treatment of the cells with palmitic acid 
increased the content of this fatty acid in TAG 
and, curiously, decreased the content of oleic 
acid (18:1) and linoleic acid (18:2). Whether this 
finding bears any biological significance 
remains to be elucidated. Analysis of TAG fatty 
acid content in lipin-2-depleted cells revealed a 
general decrease in all fatty acids (Fig. 8E). 
After palmitic acid treatment, the TAG fraction 
of lipin-2-depleted cells did not experience the 
enrichment in this fatty acid that occured in 
control cells (Fig. 8E). Collectively, these results 
indicate that human macrophages mount a 
proinflammatory response to saturated fatty 
acids, the extent of which appears to be 
controlled by lipin-2, possibly by driving the 
incorporation of these fatty acids into TAG. 
 
DISCUSSION 
Macrophages exhibit marked cellular 
responses to saturated fatty acids and play an 
important role in metabolic disorders that 
involve increased lipid exposure such as 
atherosclerosis or obesity (1-3). Saturated fatty 
acids are also known to promote ER stress and 
the activation of the UPR that ultimately 
intersects with different signaling pathways, to 
generate a low-grade chronic inflammatory state 
(9). While a great deal of effort has been put into 
unveiling the role of kinases, chaperones and 
nuclear factors in the regulation and integration 
of all of these processes, very little is known 
about the role of lipid-modifying enzyme 
effectors (9). Our data provide insights into the 
role of lipin-2 as a key player in human and 
murine macrophage proinflammatory activation 
by saturated fatty acids. Here, we demonstrate 
that lipin-2 uncouples saturated fatty acid 
activation from proinflammatory gene 
expression. We also show that reduction of 
lipin-2 expression promotes an increased 
proinflammatory state through the 
overstimulation of the JNK1/AP-1 pathway. 
Finally, we show that lipin-2 controls the 
incorporation of free fatty acids into TAGs, 
especially during fatty acid overload conditions, 
thereby reducing the damage generated. A 
schematic representation of all these findings is 
shown in Fig. 9. Collectively, the data uncover 
lipin-2 as a new player in the proinflammatory 
activation driven by saturated fatty acids, which 
suggests new opportunities for pharmacological 
intervention for the treatment of pathological 
conditions associated to these processes.  
 In our experiments, activation of 
JNK1/c-Jun appears to constitute the major 
cellular contributor to inflammatory signaling. 
This observation is in agreement with previous 
studies suggesting that hematopoietic JNK is the 
main pathway for the expression of 
proinflammatory factors and macrophage 
infiltration in the adipose tissue of mice on a 
high fat diet (3,8). 
 Recently, it has been reported that 
deletion of yeast phosphatidate phosphatase 
makes the cells more sensitive to fatty acid-
induced toxicity (38), a finding that concurs with 
the results presented here. Yeast possesses only 
one gene coding for phosphatidate phosphatase, 
while mammals possess 3 genes that encode for 
lipin proteins, and one of them, Lpin1 undergoes 
alternative splicing to generate 2 more lipin 
variants in mouse (lipin-1α and 1β) and 3 in 
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humans (lipin-1α, 1β and 1γ). Evidence is 
accumulating to indicate that some of these 
proteins may regulate distinct processes in 
cellular physiology. For example, lipin-1α and 
1β appear to control different aspects of 
adipocyte differentiation (39). The protective, 
anti-inflammatory role attributed to lipin-2 in 
this work appears to be specific for this protein, 
since depletion of either lipin-1 or lipin-3 does 
not show any appreciable effect during palmitic 
acid overload. 
 In previous work, we demonstrated that 
lipin-1 modulates size, amount and TAG fatty 
acid composition of lipid droplets in human 
macrophages (20). However, TAG synthesis 
itself does not appear to be regulated by lipin-1, 
since depletion of this protein does not affect the 
rate of fatty acid incorporation into TAG (20). In 
the current study, we have observed that TAG 
mass in lipin-2-depleted macrophages, either 
human or murine, is significantly decreased as 
compared to cells expressing normal lipin-2 
levels, and that this occurs under normal or fatty 
acid overload conditions. Putting all these 
observations together, it appears clear that in 
macrophages, lipin-1 and lipin-2 play different 
roles. On one hand, lipin-1 regulates lipid 
droplet formation by impinging upon cytosolic 
group IVA phospholipase A2-mediated signaling 
(20,40-42); on the other hand, lipin-2 acts to 
regulate cellular TAG mass levels. Lipin-2 
would be, therefore, a ‘metabolic’ enzyme, 
producing DAG moieties to accommodate fatty 
acids in TAG, thereby antagonizing the stress 
produced by excess free fatty acids.  
 The results presented in this work might 
provide clues to explain, at least in part, the 
episodes of inflammation that occur in patients 
with Majeed syndrome and psoriasis, which are 
associated to lipin-2 mutations (18,19). For 
example, in those patients who have an 
inflammatory process already ongoing, saturated 
fatty acids could produce an exacerbated 
inflammatory state in macrophages, generating 
more proinflammatory cytokines and 
contributing to the maintenance of 
inflammation. In the same line of thought, it has 
been described that obese patients with psoriasis 
are more difficult to treat than non-obese 
individuals (43,44). Several trials have 
demonstrated that psoriatic patients are partially 
recovered after weight loss and that increases in 
weight worsen the symptoms (43,44). 
 On the other hand, in a recent study with 
a Dutch population, researchers discovered a 
single nucleotide polymorphism (SNP9- 
rs3745012) within the 3´ untranslated region of 
LPIN2 that is significantly associated with type-
2 diabetes in individuals with a high body mass 
index that affects fat distribution, making it a 
candidate to be a thrifty allele (45,46). Because 
SPN9 is a non-coding polymorphism the authors 
claim that it could produce its effects by 
changing the levels of expression of LPIN2. 
While awaiting for the real consequences of this 
polymorphism, this observation is in agreement 
with our results suggesting that mutations that 
affect lipin-2 in humans may influence the 
development of conditions like type-2 diabetes 
which are related with the adipose tissue 
inflammatory state of the patient.  
 In summary, results from this work have 
unveiled a role for lipin-2 as a key participant in 
the regulation of proinflammatory gene 
expression by saturated fatty acids in 
macrophages. Our observations show that the 
expression levels of cellular lipin-2 may have 
important consequences not only for the 
incorporation of fatty acids to TAG but also for 
the damage produced by those fatty acids to the 
cell and for the proinflammatory response in 
macrophages. Because we have extended our 
studies to human macrophages, these results 
could have incidence in the development of new 
strategies to treat lipid-related low inflammation 
conditions.   
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FIGURE LEGENDS 
 
FIGURE 1. Expression of lipins and role in macrophages. A) PCR analysis of Lpin1α, 1β, 2 and 3 
mRNA expression in RAW 264.7 macrophages. B) Cells were transfected with control siRNA 
(siCtrl., open bars) or siRNA against Lpin1, 2 or 3 (siLpin1, 2 or 3, black bars) and, after 48 h, the 
levels of mRNA expression for each lipin gene was analyzed. C) Cells transfected with control 
siRNA or siRNA against Lpin1, 2 or 3 were treated with vehicle (open bars) or 300 μM palmitic acid 
(black bars) for 8 h, and mRNA levels for Il6, Ccl2 and Tnfα were analyzed by real-time PCR. Data 
are representative of at least three independent experiments. Error bars represent ± SEM (n=3).  
 
FIGURE 2. Lipin-2 levels regulate the expression of proinflammatory genes in macrophages. A) 
RAW 264.7 cells were transfected with control siRNA (siCtrl) or siRNA against Lpin2 (siLpin2) as 
indicated, treated with vehicle (open bars), 300 μM oleic acid (grey bars) or 300 μM palmitic acid 
(black bars) for 8 h, and mRNA levels for Il6, Ccl2, and Tnfα were analyzed by real-time PCR. B) 
Cellular supernatants from cells transfected as in A and treated with vehicle (open bars) or 300 μM 
palmitic acid (black bars) for 24 h were assayed for the indicated proinflammatory factors by using 
ELISA. C) Cells expressing either the pEGFP or the lipin2-EGFP plasmids, were activated with 
vehicle (open bars) or 300 μM palmitic acid (black bars) for 8 h, and the levels of mRNA for Il6, 
Ccl2 and TNFα were analyzed by real-time PCR. Data are representative of at least three independent 
experiments. Error bars represent ± SEM (n=3).  
 
FIGURE 3. Lipin-2 controls the phosphorylation levels of JNK1 and ERK. RAW 264.7 macrophages 
were transfected with control siRNA or siRNA against Lpin2 as indicated, and treated with 300 μM 
palmitic acid for the indicated periods of time. Phosphorylation levels and total protein for JNK and 
ERK were assayed by Western-blot (upper panel). β-actin levels were also assayed for protein 
loading. Relative intensity of phosphorylated bands against total protein was analyzed for JNK1, ERK 
p42 and ERK p44, and the results are represented in the lower panel. Data are representative of three 
independent experiments.  
 
FIGURE 4. Effect of JNK and ERK inhibition on the up-regulation of proinflammatory genes in 
lipin-2-deficient macrophages. A) Real-time PCR analysis of the mRNA expression levels of Il6, 
Ccl2 and Tnfα in RAW 264.7 cells transfected with control siRNA or siRNA against Lpin2. The cells 
were treated with vehicle (open bars) or 300 μM palmitic acid alone (black bars) or 300 µM palmitic 
acid plus 10 μM SP600125 (grey bars) or 10 μM PD98059 (striped bars) for 8 h. B) Cellular 
supernatants from cells transfected with control siRNA or siRNA against Lpin2, and treated exactly 
as in panel A for 24 h, were assayed for the indicated proinflammatory factors by specific ELISAS. 
Data are representative of at least three independent experiments. Error bars represent ± SEM (n=3). 
 
FIGURE 5. JNK1 mediates the up-regulation of proinflammatory genes in lipin-2-deficient 
macrophages. RAW 264.7 cells were transfected with control siRNA, siRNA against JNK1 (si 
JNK1), against Lpin2 (si Lpin2) or both, and treated with vehicle (open bars) or 300 μM palmitic acid 
(black bars). A) Real-time PCR analysis of the expression of Il6, Ccl2 and Tnfα mRNA after 8 h. B) 
Cellular supernatants after 24 h treatment were assayed for the indicated proinflammatory factors by 
specific ELISAS. Data are representative of at least three independent experiments. Error bars 
represent ± SEM (n=3). 
 
FIGURE 6. c-Jun is overactivated in lipin-2-deficient macrophages. A) RAW 264.7 macrophages 
were transfected with control siRNA or siRNA against Lpin2 and treated with 300 μM palmitic acid 
for the indicated periods of time. Phosphorylation levels and total c-Jun were assayed by Western-
blot. The lower panel represents the quantification of the relative intensity of the phosphorylated 
bands against total c-Jun protein. B) Nuclear c-Jun DNA-binding activity was assayed by a specific 
kit in cells transfected with either control siRNA or siRNA against Lpin2, and then treated with 
vehicle (open bars) or 300 μM palmitic acid (black bars) in the absence or presence of 10 μM 
SP600125 for 3 h, as indicated. Absorbance at 450 nm is shown. C) Real-time PCR analysis of the 
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expression of Il6, Ccl2 and Tnfα mRNA in cells transfected with control siRNA or with siRNA 
against c-Jun (sic-Jun), Lpin2 or both, and treated with vehicle (open bars) or 300 μM palmitic acid 
(black bars) for 8 h. Data are representative of at least three independent experiments. Error bars 
represent ± SEM (n=3). 
 
FIGURE 7. Lipin-2-deficient macrophages exhibit a diminished capacity to produce TAG. A) RAW 
264.7 macrophages transfected with control siRNA or siRNA against Lpin2 were treated with 300 
μM palmitic acid for 16 h. Cells were stained with BODYPI 493/503 and visualized by fluorescence 
microscopy. B) Cells treated as in A were analyzed by flow cytometry. Green traces refer to untreated 
cells, and red traces to palmitic acid-treated cells. Numbers close to the traces represent the mean 
fluorescence intensity for each condition. C, D) Cells transfected with control siRNA or siRNA 
against Lpin2 were treated with vehicle (green bars) or 300 μM palmitic acid (red bars) for 16 h. Fatty 
acids present in TAG were analyzed by mass spectrometry as described under Experimental 
Procedures. Total cellular TAG is represented in C, and quantification of palmitic acid (16:0) and 
stearic acid (18:0), accounting for more than 90% of total fatty acids in TAG, is represented in D. 
Data are representative of at least three independent experiments. Error bars represent ± SEM (n=3) 
(*, p<0.05). 
 
FIGURE 8. Lipin-2 controls proinflammatory gene expression and TAG storage in human 
macrophages. A) PCR analysis of LPIN1α, 1β, 2 and 3 mRNA in human macrophages. B)  Human 
macrophages were transfected with a control siRNA (open bars) or siRNA against LPIN2 (black bars) 
and then treated or not with 300 μM palmitic acid for 8 h as indicated. mRNA levels for TNFα, and 
IL6 were analyzed by real-time PCR. C) mRNA expression levels of LPIN2 in cells transfected with 
control siRNA (open bar) of against LPIN2 (black bar) for 48 h. D, E) Mass spectrometry analysis of 
fatty acids esterified into TAG of human macrophages transfected with control siRNA  or siRNA 
against LPIN2,, and treated with vehicle (open bars) or 300 μM palmitic acid (black bars) for 16 h. 
Total TAG content is shown in D, and fatty acid composition of TAG is shown in E. Data are 
representative of at least three independent experiments. Error bars represent ± SEM (n=3) (*, 
p<0.05). 
 
FIGURE 9. Role of lipin-2 in the generation of proinflammatory mediators in macrophages 
stimulated with saturated fatty acids. Saturated fatty acids such as palmitic acid impact on cellular 
homeostasis by two different mechanisms. In the first one, saturated fatty acids act through TLR4/2 
and turn on a cascade of signals that culminate in JNK/AP-1 activation. In the second mechanism, 
saturated fatty acids enter the cell and promote cellular damage. Both pathways end in the up-
regulation of proinflammatory genes by macrophages. Lipin-2, by controlling the biosynthesis of 
TAG and hence the incorporation of fatty acids into neutral lipids, attenuates the activation of JNK/c-
Jun and the levels of proinflammatory mediators such as IL-6, MCP-1 and TNFα. 
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